GYKI 53784 (LY303070) is an orally active, blood-brain penetrant, selective, non-competitive AMPA receptor antagonist ( IC 50 = 0.32 μM). GYKI 53784 completely blocks AMPA -mediated synaptic transmission, protects against excitotoxicity, and partially inhibits Kainite (Kainic acid) ( HY-N2309 ) responses, revealing both AMPA and kainate receptors. GYKI 53784 selectively blocks synaptic transmission ( IC 50 = 365.3 nM) without affecting neuronal excitability, and exhibits potent stereoselective antinociceptive effects via an opioid-independent mechanism. GYKI 53784 is a versatile tool for studying AMPA receptor function in synaptic transmission, excitotoxicity, neuroprotection, pain, and inflammation, with potential relevance to hearing loss, neonatal ischemia, neurodegenerative disorders, schizophrenia, and Alzheimer's disease.
Products | Products > Disease Areas > Ear Disease | Products > Disease Areas > Chronic Disease and Inflammation | Products > Disease Areas > Alzheimer's Disease | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Schizophrenia | Products > Disease Areas > Pain | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Signaling Pathways > Neuronal Signaling | Products > Research Areas > Neurological Disease | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > iGluR
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.